article thumbnail

M&A or affiliation improved rural hospitals' margins, reduced risk of closure: report

Fierce Healthcare

The analysis, conducted by healthcare consulting firm Dobson DaVanzo, found that among 110 rural hospitals that closed between 2011 and 2021, more than half were standalone hospitals without support from larger systems.

Hospitals 131
article thumbnail

STAT+: With big ambition — and a family name to match — Reed Jobs charts his own course in biotech

STAT

He was a sophomore studying biology at Stanford University and, up until October 2011, had always planned to pursue a career in cancer research. In the months after his father died of complications from pancreatic cancer, Reed Jobs found it difficult to go back to life as it was before.

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

US Congress passes bill to end Parkinson’s disease

pharmaphorum

The US Congress has passed the first-ever federal bill dedicated to ending Parkinson’s disease, modelled on similar legislation for Alzheimer’s enacted in 2011

119
119
article thumbnail

California Wildfires in the 2010s Exacerbated Psychotropic Medication Prescriptions

Drug Topics

Researchers studied the effect of wildfires on mental health in California from 2011 to 2018.

112
112
article thumbnail

More than 70 babies have been born from uterus transplants: ‘It’s a complete new world’

STAT

The first successful transplant was performed in 2011 — but even then, the recipient wasn’t immediately able to get pregnant and deliver a baby. The first modern attempt at transferring a uterus from one human to another occurred at the turn of the millennium.

142
142
article thumbnail

Opinion: The FDA’s risky action on compounding weight loss drugs

STAT

When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost.

article thumbnail

PTC inks Royalty deal worth up to $1.5B on Genentech-partnered SMA drug Evrydsi

Fierce Pharma

The company licensed the med to Genentech in 2011. Amid a cost-cutting drive and a looming commercial threat in Europe, PTC Ther | PTC will hold on to 19% of its royalty interest in the Genentech drug with the option to sell the rest down the line.

111
111